SNSE vs. NRXP, GBIO, ALRN, OVID, NBRV, SCYX, KZR, PEPG, SPRO, and OSTX
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include NRx Pharmaceuticals (NRXP), Generation Bio (GBIO), Aileron Therapeutics (ALRN), Ovid Therapeutics (OVID), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Kezar Life Sciences (KZR), PepGen (PEPG), Spero Therapeutics (SPRO), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry.
Sensei Biotherapeutics vs.
Sensei Biotherapeutics (NASDAQ:SNSE) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
NRx Pharmaceuticals' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.
Sensei Biotherapeutics currently has a consensus target price of $4.33, suggesting a potential upside of 862.32%. NRx Pharmaceuticals has a consensus target price of $31.67, suggesting a potential upside of 1,288.89%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Sensei Biotherapeutics.
Sensei Biotherapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
In the previous week, Sensei Biotherapeutics' average media sentiment score of 0.00 equaled NRx Pharmaceuticals'average media sentiment score.
Sensei Biotherapeutics received 12 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 80.00% of users gave Sensei Biotherapeutics an outperform vote.
10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 22.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
NRx Pharmaceuticals beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SNSE) was last updated on 2/22/2025 by MarketBeat.com Staff
